TG THERAPEUTICS, INC.

TGTX · Nasdaq · United States

Share price · TGTX

$66.12+15.86 (+31.56%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.9M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TGTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+5.4%
  2. 30 Oct 2026+5.3%

    Nothing announced by TGTX that day or the session before.

  3. 16 Sep 2026+5.3%
  4. 21 Aug 2026+7.3%

    Nothing announced by TGTX that day or the session before.

  5. 3 Aug 2026-11.3%
  6. 10 Jun 2026+7.5%
  7. 3 Jun 2026+9.5%
  8. 6 May 2026+16.3%
  9. 22 Apr 2026+5.6%
  10. 20 Apr 2026+4.6%

    Nothing announced by TGTX that day or the session before.

Share of unusual movement by asset

For each asset, the share of TGTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Ublituximab (Briumvi)
events and moves
1310%
Azercabtagene zapreleucel
events and moves
4shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—28%
Sessions with no dated event—61%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Ublituximab(Briumvi)
Approved
CD20Monoclonal antibody
Multiple SclerosisSchizophreniaMyasthenia Gravis
Phase 1
CD19Cell therapy
Multiple SclerosisDiffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
Ublituximab · BriumviPhase 3Relapsing Multiple Sclerosis
Est. primary completion 2027-01-21 · NCT05877963 · CT.gov ↗
What to watch
July 2027 (1)
Ublituximab · BriumviPhase 2Multiple Sclerosis
Est. primary completion 2027-07-31 · NCT07503873 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
Ublituximab · BriumviPhase 2Myasthenia Gravis
Est. primary completion 2028-07-01 · NCT07673744 · CT.gov ↗
What to watch
December 2028 (1)
Ublituximab · BriumviPhase 2Schizophrenia
Est. primary completion 2028-12-12 · NCT07680946 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Ublituximab · BriumviPhase 2/3Relapsing Multiple Sclerosis
Est. primary completion 2030-01-01 · NCT07220252 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Ublituximab · BriumviPhase 3Relapsing Multiple Sclerosis (RMS)
Est. primary completion 2032-05-31 · NCT04130997 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 June 2026Topline resultUblituximabPhase 1 topline of subcutaneous ublituximab (BRIUMVI) in myasthenia gravis
TG THERAPEUTICS, INC. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$260M$51M$429M+ $75M short-term inv.—$45M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$240M$95M$483M+ $70M short-term inv.—$39M operating cash flowreport ↗
2026-Q1$205M$48M$442M+ $72M short-term inv.—-$18M operating cash flowreport ↗
2025-Q3$162M$41M$74M+ $58M short-term inv.—-$23M operating cash flowreport ↗
2025-Q2$141M$32M$129M+ $123M short-term inv.—$7.4M operating cash flowreport ↗
2025-Q1$121M$46M$132M+ $144M short-term inv.—-$29M operating cash flowreport ↗
2024-Q3$84M$20M$196M+ $145M short-term inv.—-$12M operating cash flowreport ↗
2024-Q2$73M$18M$83M+ $134M short-term inv.—$5.5M operating cash flowreport ↗
2024-Q1$63M$33M$75M+ $134M short-term inv.$11M-$8.2M operating cash flowreport ↗
2023-Q3$166M$15M$151M+ $78M short-term inv.—$84M operating cash flowreport ↗
2023-Q2$16M$28M$97M+ $48M short-term inv.$48M-$42M operating cash flowreport ↗
2023-Q1$7.8M$16M$61M+ $78M short-term inv.$39M-$60M operating cash flowreport ↗
2022-Q3$0.1M$21M$110M+ $66M short-term inv.$36M-$34M operating cash flowreport ↗
2022-Q2$0.6M$27M$147M+ $49M short-term inv.$41M-$49M operating cash flowreport ↗
2022-Q1$2.0M$48M$186M+ $48M short-term inv.$69M-$69M operating cash flowreport ↗
2021-Q3—$52M$327M+ $30M short-term inv.—-$67M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$616M$160M$79M+ $63M short-term inv.—-$25M operating cash flowreport ↗

TG THERAPEUTICS, INC. reported revenue of $616.29M, up 87.3% YoY, R&D spend of $160.22M, up 69.9% YoY, cash and equivalents of $79.15M, and net income of $447.18M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$329M$94M$180M+ $131M short-term inv.—-$41M operating cash flowreport ↗
2023-FY$234M$76M$93M+ $125M short-term inv.—-$31M operating cash flowreport ↗
2022-FY$2.8M$125M$102M+ $59M short-term inv.$50M-$176M operating cash flowreport ↗
2021-FY$6.7M$223M$299M+ $16M short-term inv.$87M-$296M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($438K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-10Charney Laurence N · directorOpen-market sale5,000$54.96$275KForm 4
2026-08-07Charney Laurence N · directorGift500——Form 4
2026-08-07Charney Laurence N · directorGift450——Form 4
2026-08-06Charney Laurence N · directorGift5,100——Form 4
2026-06-11Charney Laurence N · directorAward / grant (derivative)8,325——Form 4
2026-06-11Echelard Yann · directorAward / grant (derivative)8,325——Form 4
2026-06-11Hoberman Kenneth · directorAward / grant (derivative)8,325——Form 4
2026-06-11HUME DANIEL · directorAward / grant (derivative)8,325——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 356 reporting institutions held 105.4M shares ($3.4B).

#InstitutionSharesValue
1BlackRock, Inc.22,252,930$739.2M
2STATE STREET CORP8,649,766$287.3M
3VANGUARD PORTFOLIO MANAGEMENT LLC8,273,979$274.9M
4VANGUARD CAPITAL MANAGEMENT LLC6,603,258$219.4M
5Soleus Capital Management, L.P.4,029,319$133.9M
6GEODE CAPITAL MANAGEMENT, LLC3,499,916$116.3M
7Clearbridge Investments, LLC3,210,930$106.7M
8GOLDMAN SACHS GROUP INC2,287,688$76.0M
9CONGRESS ASSET MANAGEMENT CO2,168,081$72.0M
10JANE STREET GROUP, LLC2,041,669$67.8M
11CITADEL ADVISORS LLC1,922,889$63.9M
12Pictet Asset Management Holding SA1,747,373$58.0M
13Hood River Capital Management LLC1,569,171$52.1M
14TWO SIGMA INVESTMENTS, LP1,542,312$51.2M
15BANK OF AMERICA CORP /DE/1,461,302$48.5M